Privacy Policy
Signals Blog

Contributors

Categories

Right Turn: CCRM hits the “airwaves” with its own podcast

by | Apr 15, 2022

Every day, it seems there is a new podcast vying for our attention. In specific terms, in 2021 there were 850,000 active podcasts with over 48 million total episodes. (Curious for more podcast stats? Check out this blog by Neal Schaffer.)

Podcasts are positively proliferating in the public sphere and CCRM has parachuted onto this popular platform!

As you would expect from a CCRM entry into this field, “Commercializing Living Therapies with CCRM” invites cell and gene therapy experts and influencers to comment on topics relevant to industry professionals.

Back in November 2021, I let readers know the CCRM podcast was launching soon. As promised, “Commercializing Living Therapies with CCRM” published its first podcast mid-December and it has followed up with a new podcast each month.

Whether you are a first-time listener or you missed one, here’s what you can look forward to:

  • George Church and Peter Zandstra looking to the future of synthetic biology in cell and gene therapies.
  • Rob Jones and Dr. Anthony Davies on manufacturing and supply chain issues in cell and gene therapies.
  • Cynthia Lavoie and Geoff MacKay on the business of regenerative medicine and investment.
  • Janet Rossant and Phil Vanek on how the regenerative medicine community can create broader societal awareness.

Each episode, hosted by experienced podcaster Krista Lamb, contains some gems. Please visit CCRM’s website for full descriptions, more details on the experts, and to listen. Alternatively, you can listen and subscribe on your favourite platform.

In other podcast news, BioTechniques has been podcasting for some time now. In March, they launched STEM Tea, a series hosted by Antentor Othrell Hinton Jr, an assistant professor at Vanderbilt University, who discusses the latest social, societal and scientific developments in science, technology, engineering and math (STEM), with a focus on equity, diversity and inclusion.

If you, like millions of others, are spending an average of over six hours per week listening to podcasts while you commute or walk the dog or clean your house, I encourage you to give “Commercializing Living Therapies with CCRM” a listen. I know you will find it educational, insightful and even amusing.

Our next podcast will be published mid-May. It is on the topic of reimbursement of cell and gene therapies and features Robert Woolstencroft, Senior Director and Head, Market Access and Reimbursement at Gilead Canada, and Dr. Chris McCabe, CEO and Executive Director of the Institute of Health Economics.

Let’s get you started with Episode 1, featuring Dr. Janet Rossant, President and Scientific Director, Gairdner Foundation and Dr. Phil Vanek, Chief Technology Officer, Gamma Biosciences, discussing the importance of educating the public about cell and gene therapies.

.

The following two tabs change content below.
Avatar photo
My Twitter profileMy Google+ profileMy LinkedIn profile

Stacey Johnson

Stacey Johnson is the editor of Signals and a contributor. For 25 years, Stacey has been providing strategic communications counsel to government, corporate, technology and health organizations. She began her career at the CTV Television Network and then moved to Hill & Knowlton Canada where she advised clients in a variety of industries and sectors. Stacey is the Vice President, Communications and Marketing for CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. She has a Master's degree in Public Relations. You can follow her on Twitter @msstaceyerin.

Submit a Comment

Your email address will not be published. Required fields are marked *